GSK's RSV, Shingles vaccines show on-par immune response in joint trial
Adds details on study in paragraph 2, company's statement in paragraph 4
Sept 18 (Reuters) -British drugmaker GSK GSK.L said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
The trial testing the immune response of co-administration of GSK's blockbuster vaccines, Shingrix and Arexvy, in adults over 50 years of age, met the main goal of the study.
The co-administration will help in "reducing the number of visits to the healthcare offices and pharmacies and ultimately help to get ahead of RSV and shingles," said Len Friedland, managing director and vice president of GSK's Scientific Affairs and Public Health.
RSV causes over 177,000 hospitalizations and 14,000 deaths in the United States annually, while over 1 million people develop shingles every year in the country.
GSK, one of the world's largest vaccine manufacturers, under CEO Emma Walmsley has focussed on vaccines and infectious diseases as a strategy to boost sales and counter patent expiries and declining revenue from current bestselling medicines by the end of this decade.
GSK's Shingrix and Arexvy, however, missed market expectations for second-quarter sales in July.
Reporting by Prerna Bedi in Bengaluru; Editing by Varun H K and Shinjini Ganguli
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
